IL161747A0 - Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors - Google Patents
Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitorsInfo
- Publication number
- IL161747A0 IL161747A0 IL16174702A IL16174702A IL161747A0 IL 161747 A0 IL161747 A0 IL 161747A0 IL 16174702 A IL16174702 A IL 16174702A IL 16174702 A IL16174702 A IL 16174702A IL 161747 A0 IL161747 A0 IL 161747A0
- Authority
- IL
- Israel
- Prior art keywords
- anthranilic acid
- treatment
- acid amides
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 title abstract 3
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title 1
- 108091008605 VEGF receptors Proteins 0.000 title 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 208000017442 Retinal disease Diseases 0.000 abstract 2
- 206010038923 Retinopathy Diseases 0.000 abstract 2
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 2
- 208000002780 macular degeneration Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- -1 perfluoro Chemical group 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
| PCT/EP2002/012444 WO2003040102A1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161747A0 true IL161747A0 (en) | 2005-11-20 |
Family
ID=9925448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16174702A IL161747A0 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US7091224B2 (enExample) |
| EP (1) | EP1446382B1 (enExample) |
| JP (1) | JP2005511602A (enExample) |
| KR (1) | KR100602977B1 (enExample) |
| CN (1) | CN1300113C (enExample) |
| AT (1) | ATE496889T1 (enExample) |
| AU (1) | AU2002351909B2 (enExample) |
| BR (1) | BR0213970A (enExample) |
| CA (1) | CA2463968C (enExample) |
| CO (1) | CO5580823A2 (enExample) |
| DE (1) | DE60239073D1 (enExample) |
| ES (1) | ES2360283T3 (enExample) |
| GB (1) | GB0126902D0 (enExample) |
| HR (1) | HRP20040411A2 (enExample) |
| IL (1) | IL161747A0 (enExample) |
| MX (1) | MXPA04004391A (enExample) |
| NO (1) | NO327231B1 (enExample) |
| NZ (1) | NZ532590A (enExample) |
| PE (1) | PE20030714A1 (enExample) |
| PL (1) | PL368416A1 (enExample) |
| PT (1) | PT1446382E (enExample) |
| RU (1) | RU2318811C2 (enExample) |
| SA (1) | SA02230412B1 (enExample) |
| TW (1) | TWI260222B (enExample) |
| UA (1) | UA77446C2 (enExample) |
| WO (1) | WO2003040102A1 (enExample) |
| YU (1) | YU36004A (enExample) |
| ZA (1) | ZA200402940B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
| GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
| DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
| US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
| US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
| UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
| EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
| EP1657241A1 (en) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655295A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamide pyridinureas as VEGF receptor kinase inhibitors |
| EP1820795A4 (en) | 2004-12-07 | 2010-10-20 | Toyama Chemical Co Ltd | NEW ANTHRANILIC ACID DERIVATIVE OR SALT FROM IT |
| US7547782B2 (en) * | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| CN101265274B (zh) * | 2007-02-16 | 2013-09-04 | 中国医学科学院药物研究所 | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 |
| AR073216A1 (es) | 2008-08-27 | 2010-10-20 | Leo Pharma As | Derivados de piridina como receptor de vegfr-2 e inhibidores de proteina tirosina quinasa y uso farmaceutico de los mismos |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
| CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0850222B1 (en) * | 1996-06-29 | 2003-05-28 | Samjin Pharmaceutical Co., Ltd. | Piperazine derivatives and process for the preparation thereof |
| UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
| GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
-
2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
-
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active Expired - Fee Related
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en not_active Ceased
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 EP EP02787595A patent/EP1446382B1/en not_active Expired - Lifetime
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
- 2002-11-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
-
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1446382E (pt) | Amidas do ?cido antran?lico e sua utiliza??o como inibidores da tirosina quinase do receptor de vegf | |
| ATE329596T1 (de) | Phthalazinderivate zur behandlung von entzündlicher erkrankungen | |
| MY126862A (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| BR0311221A (pt) | Derivados de 1h-imidazo[4,5-c]quinolina no tratamento de doenças dependentes de proteìna cinase | |
| AU2010206334A1 (en) | Combinations comprising methotrexate and DHODH inhibitors | |
| EA200900388A1 (ru) | Бензоксазолы и оксазолопиридины, применимые в качестве ингибиторов киназ janus | |
| MX2007000028A (es) | Derivados de nicotinamida y su uso como agentes terapeuticos. | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| HUP0400229A2 (hu) | Triaza-spiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények | |
| NO20060113L (no) | Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer | |
| PL2004653T3 (pl) | 3-Podstawione N-(arylo- lub heteroarylo)-pirazo[1,5-a]pirymidyny jako inhibitory kinazy | |
| WO2005047279A8 (en) | Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain | |
| UA91332C2 (uk) | Кристалічна малеатна сіль хіназоліну (варіанти), корисна як антиангіогенний агент | |
| EA200601418A1 (ru) | ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ | |
| DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
| MY136322A (en) | Anthranilic acid amides and pharmaceutical use thereof | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| ATE393152T1 (de) | Phtalazine derivate mit angiogenesis inhibierender wirkung | |
| DE60327249D1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
| ECSP045092A (es) | Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf | |
| UY27534A1 (es) | Amidas de ácido antranílico y uso farmacológico de las mismas. |